Scarica l'app Stockscreener
3.46
3.89%
-0.14
Dopo l'orario di chiusura:
3.44
-0.02
-0.58%
Precedente Chiudi:
$3.60
Aprire:
$3.54
Volume 24 ore:
133.82K
Relative Volume:
0.52
Capitalizzazione di mercato:
$44.15M
Reddito:
-
Utile/perdita netta:
$-15.91M
Rapporto P/E:
-2.3945
EPS:
-1.445
Flusso di cassa netto:
$-15.07M
1 W Prestazione:
-11.96%
1M Prestazione:
-10.82%
6M Prestazione:
+6.13%
1 anno Prestazione:
-5.98%
Intervallo 1D:
$3.46
$3.65
Intervallo di 1 settimana:
$3.05
$4.03
Portata 52W:
$1.11
$5.7441
Lantern Pharma Inc Stock (LTRN) Company Profile
Nome
Lantern Pharma Inc
Settore
Industria
Telefono
972-277-1136
Indirizzo
1920 MCKINNEY AVENUE, DALLAS, TX
Compare LTRN vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
3.46 | 45.93M | 0 | -15.91M | -15.07M | -1.445 |
VRTX
Vertex Pharmaceuticals Inc
|
480.25 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
663.09 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
876.25 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
183.95 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
288.06 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-10-07 | Iniziato | H.C. Wainwright | Buy |
Lantern Pharma Inc Borsa (LTRN) Ultime notizie
New to The Street Show #761 to Broadcast Across Bloomberg U.S., Latin America and MENA, Featuring Sagtec Global, Virtuix, Lantern Pharma and YY Group - ACCESS Newswire
Why Did LTRN Stock Surge 18% In Pre-Market Today? - Stocktwits
Lantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent “Computational Biologist” That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer - Business Wire
Lantern Pharma’s ZetaOmics turns plain-English questions into cancer analysis - Stock Titan
LTRN News | LANTERN PHARMA INC (NASDAQ:LTRN) - ChartMill
Lantern Pharma and Starlight Therapeutics Announce FDA Clearance - The National Law Review
LTRN Forecast — Price Target — Prediction for 2027 - TradingView
Lantern Pharma, Inc. Actuals & Estimates (BOATS:LTRN) - TradingView
LTRN Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive SurpriseConsensus Beat Rate - dars.gov.et
[EFFECT] Lantern Pharma Inc. SEC Filing - Stock Titan
Lantern Pharma Inc (LTRN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lantern Pharma Inc (LTRN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Lantern Pharma Inc (LTRN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lantern Pharma Inc (LTRN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lantern Pharma Inc (LTRN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lantern Pharma Inc (LTRN) Institutional Confidence - TradingKey
Lantern Pharma Inc (LTRN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Lantern Pharma Inc (LTRN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lantern Pharma Inc (LTRN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lantern Pharma’s Dramatic Slide Reflects Key Strategic Uncertainties - timothysykes.com
Lantern Pharma (LTRN) Faces Pressure: Shares Dip 4.67% as Technical Support at $3.69 LoomsContinuation Pattern Picks - newsline.com
LTRN Q1 2026 Earnings: Narrowed Loss Beats Expectations, Pipeline Progress Remains KeyEarnings Surprise Score - newsline.com
Lantern Pharma (LTRN) Falls 4.7% as Biotech Stock Tests Key Support ZoneDividend Growth Stocks - newsline.com
Lantern Pharma (NASDAQ: LTRN) files S-1 resale and flags funding risk - Stock Titan
Lantern Pharma (LTRN) Extends Decline: Key Support Levels in Focus After 5.28% DropRisk Parity Rebalance - newsline.com
Lantern Pharma stock jumps on lung cancer trial survival data By Investing.com - Investing.com India
Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer - BioSpace
Lantern Pharma (LTRN) Shares Promising Phase 2 Trial Results - GuruFocus
Lantern Pharma stock jumps on lung cancer trial survival data - Investing.com
Lantern Pharma reports trial data for lung cancer treatment - Investing.com
Lantern Pharma reports trial data for lung cancer treatment By Investing.com - Investing.com Nigeria
Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer - TradingView
Lantern Pharma Highlights Harmonic LP-300 Phase 2 Progress - TipRanks
Lantern Pharma (LTRN) shares Harmonic LP-300 Phase 2 trial presentation in 8-K - Stock Titan
LTRNLantern Pharma Inc Short Interest - Finviz
Lantern Pharma Edges Higher: LTRN Holds Above Support After 2.57% GainCall Spread Alert - newsline.com
Lantern Pharma Inc. (LTRN) Gains 5.74% as Shares Test Key ResistanceEase of Movement - newsline.com
LTRN Q1 2026 Earnings: Narrowed Loss Per Share Beats Estimates as Pipeline Progress ContinuesEPS Growth Report - newsline.com
Lantern Pharma Announces $9.25 Million Registered Direct Offering - geneonline.com
LTRN Technical Analysis | Trend, Signals & Chart Patterns | LANTERN PHARMA INC (NASDAQ:LTRN) - ChartMill
Lantern Pharma (LTRN) Q1 2025 Earnings Transcript - AOL.com
Lantern Pharma receives FDA clearance for trial amendments - Investing.com UK
Lantern Pharma receives FDA clearance for trial amendments By Investing.com - Investing.com South Africa
Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC - BioSpace
Lantern Pharma (LTRN) Receives FDA Support for Phase 2 Trial - GuruFocus
Lantern Pharma Inc Azioni (LTRN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Lantern Pharma Inc Azioni (LTRN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| KEYSER D JEFFREY | Director |
May 12 '26 |
Buy |
2.06 |
48,544 |
100,001 |
94,303 |
5.60%
0.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):